恩扎卢胺治疗转移性去势抵抗性前列腺癌男性中前列腺特异性抗原下降与临床结局的预后关联:一项随机临床试验
本研究为PREVAIL随机双盲安慰剂对照3期试验的事后回顾性分析,纳入恩扎卢胺组未接受化疗的转移性去势抵抗性前列腺癌男性872例,按治疗3个月内确认的最大PSA下降幅度分组(可评估795例)。结果显示,PSA下降幅度越大,总生存、影像学无进展生存、PSA无进展生存、客观缓解及生活质量恶化时间均越好,PSA闪烁现象罕见(<1%)。
要点
- 恩扎卢胺治疗3个月内PSA下降≥30%、≥50%、≥90%者分别占88%、80%、39%。
- PSA下降幅度越大,总生存及至PSA进展、影像学进展时间越长。
- PSA下降幅度越大,软组织客观缓解率越高,至生活质量恶化时间越长。
核心结论
- 恩扎卢胺治疗3个月后PSA下降幅度与更好的临床及患者报告结局强烈相关,该预后信息对患者和医疗提供者具有临床价值。
研究设计与样本
- PREVAIL研究的事后回顾性分析,该研究为国际、随机、双盲、安慰剂对照3期试验。
- 纳入恩扎卢胺组未接受过化疗的转移性去势抵抗性前列腺癌男性872例,按基线至治疗3个月确认的最大PSA下降幅度分组,可评估795例。
主要发现
- 治疗3个月后,确认的最大PSA下降≥30%者占88%(701/795)、≥50%者占80%(639/795)、≥90%者占39%(307/795),无确认的最大PSA下降或下降<30%者占12%(94/795)。
- 治疗前3个月内PSA下降幅度越大,与无PSA下降或较基线下降<30%相比,总生存、至PSA进展时间、至影像学进展时间均越长。
- PSA下降幅度越大,与无PSA下降或较基线下降<30%相比,客观软组织缓解率越高,至生活质量恶化时间越长。
- 恩扎卢胺治疗后PSA闪烁现象(先升后降)罕见(<1%)。
临床怎么用
- 原文结论指出,恩扎卢胺治疗3个月后PSA下降幅度与更好的临床及患者报告结局强烈相关,该更新预后信息对患者及其医疗提供者具有临床价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the PREVAIL study, enzalutamide provided significant improvements versus placebo in clinical outcomes in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). The association of post-treatment prostate-specific antigen (PSA) decline with clinical outcomes may provide important prognostic information. OBJECTIVE: To evaluate associations between the magnitude of PSA decline from baseline to month 3 and clinical outcomes among enzalutamide recipients. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc retrospective analysis of PREVAIL, an international, randomized, double-blind, placebo-controlled phase 3 study. Men with mCRPC and no prior chemotherapy from the enzalutamide arm were included (n=872). Patients were grouped by confirmed maximal PSA decline from baseline to month 3 of treatment (n=795 evaluable). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcomes were overall survival and radiographic progression-free survival. Secondary outcomes included PSA progression-free survival, radiographic response, and degradation of Functional Assessment of Cancer Therapy-Prostate score, which were estimated using the Kaplan-Meier method. RESULTS AND LIMITATIONS: Following 3mo of enzalutamide treatment, 88% (701/795), 80% (639/795), and 39% (307/795) of patients had postbaseline confirmed maximal PSA declines of ≥30%, ≥50%, and ≥90%, respectively, whereas 12% (94/795) had no confirmed maximal PSA decline or a decline of <30%. Greater degrees of PSA decline within the first 3mo of enzalutamide treatment were increasingly associated with longer overall survival, time to PSA and radiographic progression, higher objective soft-tissue responses, and longer time to quality-of-life deterioration than no PSA decline or declines of <30% from baseline. PSA flares (rise followed by fall) after enzalutamide treatment were rare (<1%). CONCLUSIONS: The magnitude of PSA decline after 3mo of enzalutamide therapy was strongly associated with better clinical and patient-reported outcomes. This updated prognostic information is of clinical value to this patient population and their health care providers. PATIENT SUMMARY: We report that decreases in PSA levels are closely linked to better health and survival after 3mo of enzalutamide treatment in men with metastatic prostate cancer. The PREVAIL trial is registered at clinicaltrials.gov as NCT01212991.
引用
- Armstrong AJ, Lin P, Higano CS, et al. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2018. PMID: 31274110. doi:10.1016/j.euo.2018.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。